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OBJECTIVES This study was performed to characterize the endothelial and metabolic alterations of patients
with angina and angiographically normal coronary arteries (“cardiac” syndrome X [CSX])
compared with subjects with insulin resistance syndrome (“metabolic” syndrome X [MSX])
and normal controls.
BACKGROUND Previous studies have found high endothelin-1 levels, impaired endothelium-dependent
vasodilation and insulin resistance in patients with angina pectoris and angiographically
normal coronary arteries. On the other hand, subjects with insulin resistance syndrome have
shown high endothelin-1 levels.
METHODS Thirty-five subjects were studied: 13 patients with angina pectoris and angiographically
normal coronary arteries (CSX group); 9 subjects with insulin resistance syndrome (MSX
group) and 13 normal controls. All subjects received an acute intravenous bolus of insulin (0.1
U/kg) combined with a euglycemic clamp and forearm indirect calorimetry. Endothelin-1
levels, nitrite/nitrate (NOx) levels, end products of nitric oxide metabolism, glucose infusion
rates (index of insulin sensitivity) and their incremental areas (DAUCs [area under curves])
were measured during this period.
RESULTS Basal endothelin-1 levels were higher in CSX and MSX groups than in normal controls
(8.19 6 0.46 and 6.97 6 0.88 vs. 3.67 6 0.99 pg/ml; p , 0.01), while basal NOx levels were
significantly higher in MSX group than in CSX and normal controls (36.5 6 4.0 vs. 24.2 6
3.3 and 26.8 6 3.2 mol/liter, p , 0.05). After insulin administration, the DAUCs of NOx
(p , 0.05) were lower in CSX group than in MSX and normal controls, and the DAUCs of
endothelin-1 were lower in group CSX than in normal controls. Glucose infusion rate was
significantly lower in CSX and MSx groups than in normal controls (p , 0.01), suggesting
that in both CSX and MSX groups insulin resistance is present. A positive correlation was
found between the DAUCs of nitric oxide and the AUCs of glucose infusion rate.
CONCLUSIONS Blunted nitric oxide and endothelin responsiveness to intravenously infused insulin is a typical
feature of patients with angina pectoris and angiographically normal coronary arteries and
may contribute to the microvascular dysfunction observed in these subjects. (J Am Coll
Cardiol 1999;34:1452–60) © 1999 by the American College of Cardiology
Patients with angina pectoris and angiographically nor-
mal coronary arteries (“cardiac” syndrome X [CSX]
patients) show a relative frequent condition characterized
by history of typical angina pectoris, presence of
ischemic-like ST segment changes on exercise testing and
neither obvious epicardial coronary disease nor inducible
spasm on coronary arteriography (1). Several pathophys-
iological theories have been put forward to explain this
syndrome, which has been denied, by some authors, the
dignity of a real cardiac disease (2). Others, however,
claim that these patients’ symptoms are, indeed, cardiac
in origin and relate, at least in part, to a generalized
microvascular dysfunction that also involves the coronary
circulation and limits coronary flow reserve (3– 6). In
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addition, these patients exhibit a blunted hyperemic
response to forearm ischemia (3) and often show regional
perfusion abnormalities on myocardial scintigraphy (7,8).
Recently, increased levels of endothelin-1 (ET-1) have
been found in these patients (9), suggesting that this
powerful vasoactive peptide (10) may play a role in this
syndrome. Furthermore, other studies (11–13) suggested
that CSX patients are insulin resistant and exhibit decreased
insulin-induced glucose disposal, impaired total body glu-
cose oxidation and reduced nonoxidative glucose metabo-
lism. Conversely, their liver glucose output and lipid oxida-
tion are similar to those of normal controls (11). On the
other hand, increased ET-1 levels have been also found in
insulin resistance syndrome (“metabolic” syndrome X
[MSX]), characterized by the association in the same
subject of insulin resistance, hyperinsulinemia, impaired
glucose tolerance, hypertriglyceridemia, visceral obesity and
hypertension (14). Until now, it has been impossible to
define whether the endothelial and metabolic abnormalities
previously shown in CSX patients have any association with
coronary microvascular dysfunction.
The purpose of our study was to characterize the endo-
thelial and metabolic alterations of CSX patients compared
with MSX subjects and normal controls. In particular, our
interest was extended in evaluating whether altered nitric
oxide (nitrite/nitrate [NOx]) and ET-1 responsiveness to
intravenously infused insulin is a typical feature of CSX
patients or is a common feature when insulin resistance is
present. Therefore, an intravenous insulin bolus combined
with a euglycemic clamp (14) was performed in CSX
patients, in MSX subjects without cardiovascular symptoms
and in normal controls. This approach allowed us to
evaluate simultaneously insulin sensitivity and dynamic
effects of insulin on ET-1 and NOx release. In order to
evaluate intracellular glucose metabolism, forearm muscle
indirect calorimetry was also performed.
METHODS
Patients and controls. All subjects gave informed consent
to participate in the study that was approved by the local
Ethics Committee. Thirty-five subjects were studied and
divided in three groups. The first group (CSX group)
consisted of 13 consecutive patients (eight women, five men;
age 52 6 2 years, body mass index [BMI] 24.1 6
0.5 kg/m2) with rest and/or effort angina pectoris, a repro-
ducible positive exercise test (.1-mm planar or downslop-
ing ST segment depression) and angiographically smooth
epicardial coronary arteries. In all, prolonged hyperventila-
tion and/or ergonovine administration, performed during
coronary angiography, failed to induce epicardial coronary
spasms. In these patients, all treatments were withdrawn 15
days before the study that was performed and only after an
angina-free period of at least 3 days. The second group
(MSX group) consisted of nine asymptomatic subjects with
insulin resistance syndrome (five women, four men; age
49 6 3 years, BMI 28.2 6 1.4 kg/m2). Insulin resistance
syndrome was defined by the association of impaired glu-
cose tolerance and at least three of the following alterations:
hyperinsulinemia (.96 pmol/liter), insulin resistance
(HOMA [homeostasis model assessment] index .3.94),
hypertriglyceridemia (.2.3 mmol/liter), low high-density
lipoprotein (HDL) cholesterol levels (,1.19 mmol/liter),
visceral obesity and hypertension (systolic blood pressure
.160 mm Hg and diastolic blood pressure .95 mm Hg).
The cutoff presented for each variable of the insulin
resistance syndrome was derived considering .2 standard
deviations (SD) of the mean values of group 3, which
was considered our reference normal population. Diag-
nosis of impaired glucose tolerance was made after a
standard OGTT (oral glucose tolerance test) (75 g) accord-
ing to World Health Organization criteria. In all subjects,
resting and exercise electrocardiograph (ECG) and two-
dimensional echocardiographic and Doppler studies were
normal. Five out of nine patients were affected by hyper-
tension, and in these subjects, antihypertensive therapy
was withdrawn 10 days before the study. The third group
consisted of 13 normal controls (seven women, six men; age
50 6 2 years, BMI 23.1 6 0.8 kg/m2), undergoing routine
cardiological evaluation before general surgery. In all, phys-
ical examination, chest roentgenogram, resting and exercise
ECG and two-dimensional echocardiographic and Doppler
studies were normal. They had no diabetes, hypertension,
left ventricular hypertrophy, pericardial or valve disease or
cardiomyopathy. All study subjects were nonsmokers.
In Table 1 clinical, hormonal and metabolic data of the
three groups are represented. Body weight, BMI, waist/hip
ratio, systolic and diastolic blood pressure, basal glucose,
insulin, triglyceride, total cholesterol, HDL cholesterol and
free fatty acid levels were similar in CSX group and in
normal controls. In contrast, all these variables were higher
in MSX group, as expected. Lactate (557.7 6 68.8, 643.3 6
124.6 and 553.5 6 153.7 mmol/liter), pyruvate (61.7 6 8.9,
Abbreviations and Acronyms
AUC 5 area under the curve
BMI 5 body mass index
CSX 5 “cardiac” syndrome X
ECG 5 electrocardiograph
ET-1 5 endothelin-1
FSIGT 5 frequently sampled intravenous glucose
tolerance test
FGOx 5 forearm glucose oxidation
FGSt 5 forearm glucose storage
FGU 5 forearm glucose uptake
GIR 5 glucose infusion rate
HDL 5 high-density lipoprotein
MSX 5 “metabolic” syndrome X
NOx 5 nitrite/nitrate
RIA 5 radioimmunoassay
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78.2 6 26.1 and 61.6 6 14.8 mmol/liter) and alanine levels
(242 6 26.3, 246.5 6 21.5 and 195.4 6 12.2 mmol/l) were
similar in the three groups.
Experimental protocol. All subjects were admitted to the
metabolic unit in the morning after an overnight fast, and
samples were withdrawn after at least 30 min of rest in the
supine position. On the morning of each test, a 20-gauge
plastic cannula (Abbocath T; Abbot, Ireland Ltd., Sligo,
Ireland) was inserted in a dorsal hand vein of one hand, in
retrograde position, and the hand was placed in a plexiglass
box and maintained at 55°C for intermittent sampling of
arterialized blood. In order to monitor the arterial blood
glucose and accurately infuse glucose to maintain blood
glucose at baseline levels, it is necessary to arterialize venous
blood by heating the hand. This is the method of choice
because obtaining arterial samples is difficult and is associ-
ated with some risks related to arterial cannulation. Many
investigators have, therefore, used the arterialized venous
blood samples obtained from the heated hand to measure
blood glucose levels during a euglycemic hyperinsulinemic
clamp. A 20-gauge plastic cannula was inserted into a large
antecubital vein of the same arm for infusions. Another
18-gauge plastic cannula was inserted into a large, deep
antecubital vein of the controlateral arm for intermittent
sampling of deep venous forearm blood.
After a 30-min period of equilibration, all subjects re-
ceived an intravenous bolus of 0.1 U/kg insulin diluted in
1 ml saline (14) combined with the euglycemic clamp
technique (15). The intravenous bolus of insulin, or insulin
tolerance test (ITT), used since 1971 (16) and more recently
revised by Bonora et al. (17), is a well-known and simple
method to evaluate insulin sensitivity. The only modifica-
tion carried out in the present study was the addition of a
euglycemic clamp to avoid the influence of counterregula-
tory hormones on endothelial factor release. The euglycemic
clamp technique (15) is a widely used method by which
blood glucose levels are maintained at baseline values by
means of a variable 20% glucose infusion according to the
blood glucose measurements obtained every 5 min. By using
this method, the amount of glucose infused during the test
corresponds to the degree of insulin sensitivity of the
subjects.
To validate our method, we assessed the relationship
between insulin sensitivity measured with our insulin bolus
test and the insulin sensitivity index measured with the
frequently sampled intravenous glucose tolerance test
(FSIGT), according to Bergman et al. (18)—another test
that is considered a reference test for the measurement of
insulin sensitivity. We found that there was a highly
significant correlation between the two insulin sensitivity
indices (r 5 0.80, p , 0.01). The choice to use the FSIGT
as a reference method for our test was related to the fact that
in both cases, during the first 60 min of the test, insulin
levels are not in steady state.
Because, during the euglycemic clamp studies, arterial-
ized instead of arterial samples were performed, in a
previous study, we evaluated whether arterialized ET-1
levels are a reliable index of forearm arterial levels (14). In
the preparatory study, we found that there was a highly
significant correlation between arterial and arterialized
ET-1 levels in 30 subjects (r 5 0.96; p , 0.001) with a slope
not different from 1 (0.93 6 0.51; p , 0.5) and an intercept
not different from 0 (0.140 6 0.05; p , 0.6). In the present
study, we evaluated whether arterialized NOx levels are a
reliable index of forearm arterial levels. Arterial and arteri-
alized samplings were obtained simultaneously in 20 sub-
jects (5 CSX patients, 7 MSX subjects and 8 normal
controls). There was a highly significant correlation between
arterial and arterialized NOx levels (r 5 0.90; p , 0.001),
with a slope not different from 1 (0.93 6 0.11; p , 0.16)
and an intercept not different from 0 (1.32 6 2.86; p ,
Table 1. Clinical, Hormonal and Metabolic Details of the Subjects in the Study (Mean 6 SE)
CSX
Group
MSX
Group
Normal
Controls
Gender (M/F) 5/8 4/5 6/7
Age (years) 52 6 2 49 6 3 50 6 2
Weight (kg) 66.4 6 2.4 75.3 6 5.2 65.5 6 3.1
BMI (kg/m2) 24.1 6 0.5 28.3 6 2.3* 23.1 6 0.8
Waist/hip ratio 0.89 6 0.01 0.98 6 0.03* 0.88 6 0.01
Systolic blood pressure (mm Hg) 129 6 4 146.0 6 3† 120.0 6 3
Diastolic blood pressure (mm Hg) 74 6 2 90 6 2† 79 6 2
B Glucose (mmol/liter) 5.11 6 0.17 5.50 6 0.63 4.86 6 0.14
S Insulin (pmol/liter) 55.6 6 6.9 129.0 6 12.2* 40.0 6 6.6
S Triglycerides (mmol/liter) 1.27 6 0.11 3.08 6 0.35* 1.11 6 0.08
P Free fatty acids (mmol/liter) 0.75 6 0.16 0.83 6 0.10 0.63 6 0.06
S Cholesterol (mmol/liter) 5.72 6 0.20 5.98 6 0.20 5.84 6 0.45
S HDL cholesterol (mmol/liter) 1.35 6 0.34 1.05 6 0.07* 1.52 6 0.33
Data are means 6 SE. *p , 0.05 vs. CSX and normal controls; †p , 0.01 vs. CSX and normal controls.
B 5 blood; CSX 5 “cardiac” syndrome X; MSX 5 “metabolic” syndrome X; P 5 plasma; S 5 syndrome.
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0.11). Therefore, arterialized ET-1 and NOx levels are a
reliable index of forearm arterial levels.
Arterialized samples for ET-1, NOx and insulin were
withdrawn at time 230, 220, 210, 0, 1, 3, 5, 10, 15, 20,
30, 45 and 60 min after the insulin bolus. Arterialized and
deep venous samples for glucose and intermediate metabo-
lite (lactate, pyruvate, alanine) measurements were with-
drawn at 230, 215, 0, 5, 10, 15, 20, 30, 45 and 60 min.
Arterialized samples for triglyceride and free fatty acid
measurements were drawn at 25 and 0 min. This test thus
permits simultaneous evaluation of insulin sensitivity, fore-
arm indirect calorimetry, ET-1 and NOx response to
insulin.
Blood flow and blood pressure measurements. Blood
flow of the proximal forearm was measured immediately
after each blood sample by venous occlusion plethysmogra-
phy at time 230, 215, 0, 5, 10, 15, 20, 30, 45 and 60 min.
Two cuffs were inflated simultaneously to obtain a collecting
pressure of 60 mm Hg and a wrist occlusion pressure of
220 mm Hg. Changes in forearm volume were measured by
means of a temperature-compensated mercury rubber strain
gauge placed distally to the tip of the cannula, as previously
reported (19). Blood flow was expressed in ml/min/100 ml
forearm tissue volume. In addition, at least three determi-
nations of arterial blood pressure were performed at 10-min
intervals after the start of the test.
Forearm metabolite balance and forearm indirect calo-
rimetry studies. Forearm balances of glucose, lactate, pyru-
vate and alanine were calculated by using the Fick principle:
(arterialized blood concentration) 2 (deep venous blood
concentration) 3 forearm blood flow. Forearm glucose
oxidation (FGOx) rates were estimated by forearm indirect
calorimetry using arterialized and deep venous blood sam-
ples obtained at 230, 215, 0 min and every 15 min after the
start of the test, for the measurements of O2 and CO2 as
previously published in non–steady-state conditions (19,20).
In addition, in order to evaluate the degree of blood CO2
variability in the same subject in the absence of external
stimulation, eight subjects were studied in the fasting state,
and arterialized and deep venous CO2 content was mea-
sured every 15 min for 1 h. The coefficients of variation
(CV) of the arterialized and deep venous CO2 were 2.0 6
0.3% and 3.34 6 0.26%, respectively.
Three sets of arteriovenous measurements were per-
formed at each time point. Forearm O2 consumption (VO2)
and CO2 production (VCO2) were calculated as the product
of the arterialized-venous difference and forearm blood flow.
FGOx was derived according to Natali et al. (21), and
nonoxidative glycolysis was derived as the net balance of
lactate, pyruvate and alanine, in glucose equivalents. In
addition, forearm glucose storage (glycogen formation
[FGSt]) was calculated as the difference between glucose
uptake and the sum of glucose oxidation and nonoxidative
glycolysis (22).
Assays. Blood glucose was measured with a glucose-
oxidase based analyzer (YSI, Yellow Springs, Ohio). Sam-
ples for intermediate metabolite measurements were col-
lected into weighted tubes containing chilled 0.5M
perchloric acid. All samples were assayed for metabolites
and insulin in a single assay. Alanine (intraassay CV 3%,
interassay CV 3%), lactate (intraassay CV 4.0%, interassay
CV 7.5%) and pyruvate (intraassay CV 8.0%, interassay CV
9.5%) were assayed using automated enzymatic spectrofluo-
rimetric methods adapted to COBAS FARA II (Roche,
Basel, Switzerland) (23). Plasma-free fatty acid (intraassay
CV 3%, interassay CV 3%) and serum triglyceride levels
were measured using automated enzymatic spectrophoto-
metric techniques adapted to COBAS FARA II (Roche,
Basel, Switzerland). Serum insulin levels (intraassay CV
3.0%, interassay CV 5.0%) were measured by radioimmu-
noassay using commercial kits (Insulin I125 Ria kit; Incstar
Corporation, Stillwater, Minnesota).
ET-1 samples were measured with a commercial radio-
immunoassay (RIA) kit (Biomedica Gruppe, Wien, Ger-
many). In particular, in order to enrich the peptide from the
plasma sample to measurable values, ET-1 was extracted on
SepPack C18, and the eluate was evaporated in a Speedvac
concentrator (Speed Vac SC110, Savant, Roma, Italy). The
samples were then reconstituted in 250 ml of RIA buffer and
assayed. In the RIA kit, the antiserum was a rabbit-anti-
ET-1 antibody, and the tracer was I125-labeled ET-1. An
intraassay CV of 3.0%, and an interassay CV of 11.9% were
reported.
Nitrite/nitrate levels were evaluated through the mea-
surement of metabolic end products, that is, nitrite and
nitrate, using enzymatic catalysis coupled with Griess reac-
tion, as previously reported (24).
Forearm arterialized and venous blood gas samples were
analyzed at the patient’s bedside (Corning Medical and
Scientific, Medfield, Massachusetts). Plasma CO2 content
was calculated from measured CO2 tension and pH, and
adjusted to whole CO2 blood content using an empirically
derived regression equation (25). O2 content was calculated
from the hemoglobin content and percent of saturation,
using a constant of 1.34. The CV was calculated for each
individual, and the mean of intrasubject CVs were 0.1% for
pH, 0.6% for arterialized CO2, 1.3% for forearm venous
CO2 and 1.5% for arterialized O2, while mean intrasubject
CV was 4.6% for venous O2 content.
Statistical analysis. All values are expressed as mean 6
standard error at each time interval. Areas under the curves
(DAUCs) were calculated for each parameter by the trape-
zoidal rule. Comparisons within groups were performed by
means of Student t test for paired data. Comparisons among
groups were performed by means of analysis of variance
followed by the Scheffe F test when indicated. Linear
regression analyses or Spearman test were used as appropri-
ate. A two-tailed probability level of less than 0.05 was
considered statistically significant.
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RESULTS
Basal levels. Basal ET-1 levels were significantly higher in
CSX and MSX groups than in normal controls (8.19 6 0.46
and 6.97 6 0.88 vs. 3.67 6 0.99 pg/ml, p , 0.01; Fig. 1),
while no differences were found between CSX and MSX
groups. Nitrite/nitrate levels were higher in MSX group
than in CSX group and in normal controls (36.5 6 4.0 vs.
24.2 6 3.3 and 26.8 6 3.2 mmol/liter, p , 0.05; Fig. 1),
while no differences were found between CSX group and
normal controls.
Arterial systolic and diastolic blood pressures were signif-
icantly higher in MSX group than in CSX group and in
normal controls (p , 0.01, Fig. 1), while forearm blood flow
was similar in the three groups.
Forearm glucose uptake (FGU), FGOx, nonoxidative
glycolysis, FGSt and lipid oxidation (data not shown) were
similar in the three groups (Fig. 2).
Insulin effects on endothelium activity and blood pres-
sure. One minute after the insulin bolus, insulin levels
peaked at about 5,000 pmol/liter in the three groups and
rapidly declined to basal levels; blood glucose was success-
fully clamped to the baseline with a CV below 6%.
In Figure 1, ET-1, NOx, blood pressure and forearm blood
flow levels after insulin bolus are reported. Endothelin-1
response was flat in CSX group, while a significant increase
in ET-1 levels was elicited in MSX group, similar to that
observed in normal controls. This determined a significantly
lower DAUC of ET-1 in CSX group than in normal controls,
while there were no significant differences between MSX
group and normal controls. Nitrite/nitrate levels did not
significantly increase in CSX group, while they increased
significantly, with a similar pattern, in MSX group and in
normal controls. Nitrite/nitrate levels remained significantly
higher in MSX group than in CSX group, while no
differences were found between MSX group and normal
controls. The DAUCs of NOx were significantly lower in
CSX group than in MSX group and in normal controls (p ,
0.01), while no differences were found between MSX group
and normal controls.
After insulin bolus, arterial systolic and diastolic blood
pressure slightly decreased in all groups, however, blood
pressure remained significantly higher in MSX group than
in CSX group and in normal controls.
Forearm blood flow remained unchanged in CSX group,
while it significantly decreased during the first 15 min in
MSX group, returning at basal levels in the second half of
the test. On the contrary, forearm blood flow was signifi-
cantly higher during the last 30 min of the test in normal
controls.
Insulin effects on glucose utilization and forearm indirect
calorimetry. In Figure 2, the patterns of glucose utilization
and forearm glucose metabolism after insulin bolus are
reported.
Glucose infusion rates (GIRs) were significantly lower in
CSX and MSX groups than in normal controls throughout
the test. The AUCs for GIR were significantly lower in
CSX and MSX groups than in normal controls (1,242.2 6
126.7 and 651.4 6 66.1 vs. 2,143.6 6 178.7 mM/kg/min;
p , 0.05).
It is interesting that the DAUC of GIR was significantly
higher in CSX than MSX group (p , 0.05). A similar
pattern was observed in FGU. DAUCs of FGOx were
Figure 1. ET-1, NOx, systolic and diastolic blood pressure and
forearm blood flow levels after an intravenous administration of 0.1
U/kg of insulin in 13 CSX patients (circles), in 9 MSX subjects
(triangles) and in 13 normal controls (squares). Histograms
represent DAUCs for the different parameters in CSX patients
(filled bars), in MSX subjects (hatched bars) and in normal
controls (open bars). Data are means 6 SE. Blood Press. 5 blood
pressure; ET-1 5 endothelin-1; F. Blood Flow 5 forearm blood
flow; NOx 5 nitrite/nitrate. #p , 0.05 vs. basal; *p , 0.05 vs.
normal controls; §p , 0.01 vs. normal controls; †p , 0.05 vs. CSX
patients.
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significantly lower in CSX and MSX groups than in normal
controls without differences between the two groups.
Nonoxidative glycolysis tended to be greater in CSX
group, while it remained similar to baseline in MSX group
and slightly decreased in normal controls. The DAUC of
FGSt was lower in MSX group than in normal controls
(44.1 6 20.3 vs. 116.3 6 23.3 mmol/100 ml forearm/min;
p , 0.05). In CSX group, the DAUC of FGSt was 106.4 6
48.7 mmol/100 ml forearm/min (NS vs. normal controls).
The profiles and the DAUC of lipid oxidation were similar
in all groups (data not shown).
By pooling all the subjects of the three groups, a negative
correlation was found between basal ET-1 levels and the
DAUC of NOx levels (r 5 20.34, p , 0.05; data not
shown). In addition, a negative correlation between basal
ET-1 levels and FGU was observed (r 5 20.47; p , 0.01;
data not shown) and a positive correlation was found
between the AUCs of GIR and NOx levels (r 5 0.38; p ,
0.05; Fig. 3).
DISCUSSION
The aim of the study was to evaluate whether an unbalance
between ET-1 and NOx release exists in patients with
angina pectoris and angiographically normal coronary arter-
ies and whether it is typical of this disease or is a common
feature of subjects with insulin resistance syndrome. An
attempt was also made to investigate whether the observed
alterations in insulin action on glucose metabolism might be
Figure 2. GIR FGU and forearm glucose metabolism after an intravenous administration of 0.1 U/kg of insulin in 13 CSX patients
(circles), in 9 MSX subjects (squares) and in 13 normal controls (triangles). Histograms represent DAUCs for the different parameters
in CSX patients (filled bars), in MSX subjects (hatched bars) and in normal controls (open bars). Date are means 6 SE. GIR 5 glucose
infusion rate; FGU 5 forearm glucose uptake; FGOx 5 forearm glucose oxidation. *p , 0.05 vs. normal controls; †p , 0.05 vs. CSX
patients.
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related to an impairment in the insulin-induced release of
endothelial factors.
In the present study, we found that there are some
similarities between “cardiac” and “metabolic” syndrome X
concerning the presence of high basal ET-1 levels and
insulin resistance in both groups. On the other hand, the
evaluation of the dynamic response after insulin stimulation
demonstrated that there are some important differences
between the two syndromes, such as the presence of
different basal NOx levels and insulin-stimulated ET-1
and NOx releases. In addition, MSX subjects were more
insulin resistant, and insulin-mediated FGSt was compro-
mised only in these subjects. Similarities and differences
between “cardiac” and “metabolic” syndrome X related to
endothelial-factor release and insulin sensitivity are reported
in Table 2.
Insulin-stimulated endothelial release. The finding that
in CSX patients insulin is not effective in stimulating NOx
release is new. In normal controls, Baron (26) and Steim-
berg et al. (27) demonstrated that insulin-mediated vasodi-
lation is largely dependent on the action of insulin on nitric
oxide activity. To our knowledge, our data are the first to
provide direct evidence that insulin-induced release of
endothelium-derived relaxing factors is impaired in CSX
patients and also to confirm the hypothesis that in subjects
with insulin resistance, vasodilation is impaired (28–30).
Indeed, after insulin injection, forearm blood flow signifi-
cantly increased by 11% only in normal controls. However,
different results were found when measuring the effect of
insulin on NOx release in CSX and MSX patients. In CSX
patients, basal NOx levels were normal, and the insulin-
induced NOx release was severely impaired, while in MSX
subjects, basal NOx levels were high, and the insulin-
induced NOx release was normal. To explain these apparent
discordant data, we postulate that in CSX patients the
defect in vasodilation could be related primarily to a defect
in nitric oxide synthesis, as previously suggested by Egashira
et al. (6), while in MSX subjects, the defect in vasodilation
could be due to a defect in the second messenger activity,
indicating an impairment in the intracellular NO/cGMP
signaling cascade. Further support to this hypothesis comes
from previous in vitro studies, showing that rat skeletal
muscle of insulin-resistant (obese Zucker; fa/fa) rats pos-
sesses multiple defects in the nitric oxide/cyclic GMP
pathway (31). Moreover, a selective cyclic-GMP phospho-
diesterase inhibitor, zaprinast, was able to increase cyclic-
GMP levels and glucose utilisation in incubated soleus
muscle isolated from lean, but not obese, insulin-resistant
Zucker rats (31).
Insulin-mediated glucose metabolism. In our study, sim-
ilar to MSX subjects, the presence of supraphysiological
insulin levels did not overcome the defect in insulin sensi-
tivity in CSX patients. However, even if CSX patients and
MSX subjects are less sensitive to insulin than normal
controls, the degree of insulin resistance is different in the
two groups, and, in particular, MSX subjects are signifi-
cantly more insulin-resistant than CSX patients.
The presence of insulin resistance in CSX patients has
already been described by Botker et al. (11), who found a
reduction in total body glucose disposal and oxidation at
physiological insulin levels (about 770 pM). Taking the
results of both studies together, it is tempting to speculate
that in CSX patients the metabolic action of insulin is
defective and involves aerobic glycolysis and that such a
defect might involve the skeletal muscle as well as the heart
(32). In Figure 2, an uncoupling of glycolysis and glucose
oxidation in response to insulin in CSX patients can be
observed. Similar data, but relative to myocardial metabo-
lism, have been reported in these patients by Egashira et al.
(6) and Camici et al. (32). In the first study, an increase in
myocardial lactate production was found after papaverine
infusion (6), while in the second study, carbohydrate oxi-
dation was not stimulated by pacing, and net pyruvate
release was observed at maximal pacing and during recovery
(32). In the present study, an increase in skeletal muscle
nonoxidative glycolysis was also found in MSX subjects.
From our data, it is impossible to draw any conclusion about
the effect of insulin on myocardial metabolism in these
subjects, although a normal insulin-induced myocardial
glucose uptake has been found in patients with non–insulin-
dependent diabetes mellitus despite a severe decrease in
insulin-induced skeletal glucose uptake (33). Although eval-
uation of myocardial lactate production in subjects with
insulin resistance syndrome was beyond the scope of the
present study, we believe that this issue requires further
investigation.
Another important difference between “cardiac” and
“metabolic” syndrome X was related to glucose storage
measured during the test, which was correctly efficient in
CSX patients while severely impaired in MSX subjects.
These findings suggest that MSX subjects show a more
severe impairment in the intracellular partitioning of muscle
glucose metabolism.
Figure 3. Relationship between the AUCs of GIR and the
DAUCs of NOx levels in 13 CSX patients (circles), in 9 MSX
subjects (triangles) and in 13 normal controls (squares). Nox 5
nitrite/nitrate; GIR 5 glucose infusion rate.
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Relationship between endothelial factors and glucose
metabolism. One interesting finding of the present study
was the existence of a relationship linking endothelial
factors and insulin action to glucose metabolism, as dem-
onstrated by the positive correlations between the AUCs of
GIR and the DAUCs of NOx levels. However, our data do
not allow us to clarify whether insulin resistance in these
subjects was mediated by a blunted response of NOx to
insulin or by ET-1 overproduction, or both. Further studies
are required to answer this question, although a negative
correlation between basal ET-1 levels and FGU could
suggest that ET-1 might directly influence glucose metab-
olism.
Clinical implications. Whereas previous studies have
shown a strict correlation between the increment in triglyc-
eride and insulin levels and the presence of high ET-1 levels
in MSX subjects without myocardial complications (14), the
mechanism responsible for the increase in basal ET-1 levels
in CSX patients remains unknown. In fact, the latter group
of subjects did not show hypertension (34), hyperinsulin-
emia, hypertriglyceridemia and diabetes (14) or other dis-
eases, such as ischemic heart disease (35) and atherosclerosis
(36), that could determine or be determined by a sustained
stimulation of ET-1 release. In a previous study, the chronic
administration of L-arginine decreased ET-1 levels and
angina episodes in CSX patients (37), suggesting that there
is a defect of nitric oxide activity (possibly synthesis) in these
subjects. The findings of the present study may confirm this
hypothesis—but only because of the supraphysiological
insulin levels.
Study limitations. In the present study, we used the
forearm balance technique to measure FGU before and after
insulin administration. Although, from the existing litera-
ture, it frequently appears that the forearm technique is used
to measure FGU during a perturbation (19,20,38–41), this
approach does have limitations. In fact, the assessment of
glucose uptake across the forearm hinges upon the Fick
principle, which is valid only at steady-state conditions
when blood flow is constant and arterial and venous glucose
concentrations are stable. Under non–steady-state condi-
tions, when blood flow or glucose concentrations change in
time, the Fick principle does not hold, and systematic errors
may affect the estimated fluxes. Therefore, the FGU results
obtained in the present study during the insulin perturba-
tion provide only qualitative insights into insulin-stimulated
FGU in the two groups. On the other hand, even though
there were systematic errors, they were likely to affect all
groups to a similar extent. As a result, the time course of the
difference among the FGUs in CSX patients, MSX subjects
and normal controls was probably more reliable than the
individual FGU profiles, suggesting an impairment of FGU
in CSX patients and MSX subjects. As a matter of fact, the
difference between the profiles of FGU at the regional level
parallels the difference between the profiles of GIRs mea-
suring glucose metabolism (glucose uptake, plus production)
at the whole-body level. This is confirmed by a direct,
significant correlation between the DAUCs of FGU and the
AUCs of GIR (r 5 0.43; p , 0.01). All in all, we are
confident that our results suggesting a defect of insulin
activity on glucose uptake in CSX patients are correct.
Conclusions. In summary, similar to MSX subjects, CSX
patients show high basal ET-1 levels and insulin resistance.
On the other hand, CSX patients exhibit a decrease of NOx
and ET-1 release after insulin stimulation, while MSX
subjects show high basal NOx levels, normal NOx release
after insulin stimulation and a severe impairment of glucose
storage.
In conclusion, blunted nitric oxide and endothelin re-
sponsiveness to intravenously infused insulin is a typical
feature of CSX patients and may contribute to the micro-
vascular dysfunction observed in these subjects.
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Table 2. Similarities and Differences Between “Cardiac” and “Metabolic” Syndrome X
“Cardiac”
Syndrome X
“Metabolic”
Syndrome X
Endothelial factors
Basal NOx Normal High
Basal ET-1 High High
Insulin-mediated NOx Blunted Normal
Insulin-mediated ET-1 Blunted Normal
Insulin sensitivity
Insulin-stimulated glucose infusion rate Decreased Highly decreased
Insulin-stimulated forearm glucose intake Decreased Highly decreased
Insulin-stimulated forearm glucose oxidation Highly decreased Highly decreased
Insulin-stimulated forearm glucose storage Normal Highly decreased
Insulin-stimulated non-oxidative glycolysis Slightly increased Slightly increased
ET-1 5 endothelin-1; NOx 5 nitrite/nitrate.
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